C

CAR-T

Product

Heard in 8 episodes across 7 shows since Apr 2026

CAR-T is a personalized cancer immunotherapy in which a patient’s T cells are genetically engineered to recognize and attack cancer cells.

Discussed inMarkets100%

Episodes

8
across 7 shows

This week

0
episodes on 0 shows

Expert statements

12
11 positive · 1 negative

Share of the conversation

Mentions of CAR-T per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.

0.0‰0.02‰0.04‰0.06‰Aug 25Sep 16Oct 9Oct 31Nov 22
Show the data
DayShare (7-day)Mentions
Aug 310.02‰2
Sep 20.03‰1
Oct 190.01‰1
Nov 130.01‰1
Nov 150.02‰1
Nov 200.02‰1

The full trend: rank, tone and why it is trending →

Email alert

Email me when CAR-T comes up on a podcast

One email a week at most, with the new episodes that mention CAR-T. Free, no account needed, unsubscribe in one click.

What experts have said about CAR-T

12 statements · 11 positive · 1 negative

  1. Yaron WerberPositiveNov 6, 2026· Biotech Hangout

    In vivo CAR-T showed approximately 100% response rates durable through five months.

    “everybody is essentially at 100% response rate and fairly durable up to five months.”

    Listen at 59:21

    Open the episode · Episode 202 - November 6, 2026
  2. Yaron WerberPositiveNov 6, 2026· Biotech Hangout

    In vivo CAR-T appears promising based on early data.

    “it looks like in vivo car t is is fairly promising”

    Listen at 59:42

    Open the episode · Episode 202 - November 6, 2026
  3. CAR-T therapy is highly effective for blood cancers such as multiple myeloma.

    “for blood cancers like multiple myeloma, the efficacy is incredible with CAR T therapies now.”

    Listen at 1:35:08

    Open the episode · Nvidia's Historic Quarter, SaaS Comeback, Bessent vs Druck, America's Debt Crisis, Cancer Vaccine

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

8 episodes featuring CAR-T, newest first